目的观察慢病毒介导的RNAi沉默IL-1Ⅰ型受体对实验性大鼠膝骨关节炎(osteoarthritis,OA)中的丝裂素原激活的蛋白激酶(mitogen-activated protein kinase,MAPK)途径的影响,探讨IL-1和MAPK在OA中的作用。方法40只SD大鼠随机分为A～D4组,每...目的观察慢病毒介导的RNAi沉默IL-1Ⅰ型受体对实验性大鼠膝骨关节炎(osteoarthritis,OA)中的丝裂素原激活的蛋白激酶(mitogen-activated protein kinase,MAPK)途径的影响,探讨IL-1和MAPK在OA中的作用。方法40只SD大鼠随机分为A～D4组,每组10只。A～C组行单侧前交叉韧带和内侧半月板前1/3切除术,分别于术后第7和9天,A组关节腔中注射慢病毒介导IL-1Ⅰ型受体有效RNA干扰片段,B组注射慢病毒介导IL-1Ⅰ型受体无效RNA干扰片段,C组单纯注射生理盐水。D组为正常动物不做处理。术后4周处死动物,对关节软骨的状况进行评分。取膝关节软骨组织,用Western blot方法检测软骨组织中p38、ERK1/2和JNK1/2的蛋白质表达水平。结果大体观察显示:A组软骨退行性变显著轻于B、C组(P<0.05),但高于D组(P<0.05)。Western blot显示,A组p38蛋白质表达水平显著低于B、C组(P<0.05),与D组没有显著性差异(P>0.05)。A组ERK1/2和JNK1/2的表达显著低于B、C组(P<0.05),但要显著高于D组(P<0.05)。结论慢病毒介导RNA干扰沉默IL-1Ⅰ型受体能抑制MAPK的表达,特别是对其中的p38蛋白质抑制更为明显。展开更多
AIM：To explore the role of Pioglitazone（Pio） on a mouse model of retinal ischemia/reperfusion（I/R） injury and to elucidate the potential mechanism.METHODS：Retinal ischemia was induced in mice by increasing the i...AIM：To explore the role of Pioglitazone（Pio） on a mouse model of retinal ischemia/reperfusion（I/R） injury and to elucidate the potential mechanism.METHODS：Retinal ischemia was induced in mice by increasing the intraocular pressure,and Pio was administered 4 h though periocular injection before I/R.The number of cells in the ganglion cell layer（GCL） was counted 7 d after retinal I/R injury.Glial fibrillary acidic protein（GFAP）,nuclear factor-kappa B（NF-κB）,p38,phosphorylated-p38,PPAR-γ,interleukin-1β（IL-1β）,Toll-like receptor 4（TLR4）,NLRP3,cleaved caspase-1,caspase-1 were determined by real-time polymerase chain reaction and Western blotting.RESULTS：Pio promoted the survival of retinal cells in GCL following retinal I/R injury（P〈0.05）.Besides,retinal I/R injury stimulated the expression of GFAP and TLR4,which were partially reversed by Pio treatment（P0.05）.Retinal I/R injury-upregulated expression of NLRP3,cleaved caspase-1,IL-1β was attenuated after Pio treatment（P〈0.05）.Moreover,I/R injury induced activation of NF-κB and p38 were inhibited by Pio treatment（P〈0.05）.CONCLUSION：Pio promotes retinal ganglion cells survival by suppressing I/R-induced activation of TLR4/NLRP3 inflammasomes via inhibiting NF-κB and p38 phosphorylation.展开更多
文摘目的观察慢病毒介导的RNAi沉默IL-1Ⅰ型受体对实验性大鼠膝骨关节炎(osteoarthritis,OA)中的丝裂素原激活的蛋白激酶(mitogen-activated protein kinase,MAPK)途径的影响,探讨IL-1和MAPK在OA中的作用。方法40只SD大鼠随机分为A～D4组,每组10只。A～C组行单侧前交叉韧带和内侧半月板前1/3切除术,分别于术后第7和9天,A组关节腔中注射慢病毒介导IL-1Ⅰ型受体有效RNA干扰片段,B组注射慢病毒介导IL-1Ⅰ型受体无效RNA干扰片段,C组单纯注射生理盐水。D组为正常动物不做处理。术后4周处死动物,对关节软骨的状况进行评分。取膝关节软骨组织,用Western blot方法检测软骨组织中p38、ERK1/2和JNK1/2的蛋白质表达水平。结果大体观察显示:A组软骨退行性变显著轻于B、C组(P<0.05),但高于D组(P<0.05)。Western blot显示,A组p38蛋白质表达水平显著低于B、C组(P<0.05),与D组没有显著性差异(P>0.05)。A组ERK1/2和JNK1/2的表达显著低于B、C组(P<0.05),但要显著高于D组(P<0.05)。结论慢病毒介导RNA干扰沉默IL-1Ⅰ型受体能抑制MAPK的表达,特别是对其中的p38蛋白质抑制更为明显。
基金Supported by National Natural Science Foundation of China(No.81300777)the General Program of Shanghai Municipal Health and Family Planning Commission(No.201440522)
文摘AIM：To explore the role of Pioglitazone（Pio） on a mouse model of retinal ischemia/reperfusion（I/R） injury and to elucidate the potential mechanism.METHODS：Retinal ischemia was induced in mice by increasing the intraocular pressure,and Pio was administered 4 h though periocular injection before I/R.The number of cells in the ganglion cell layer（GCL） was counted 7 d after retinal I/R injury.Glial fibrillary acidic protein（GFAP）,nuclear factor-kappa B（NF-κB）,p38,phosphorylated-p38,PPAR-γ,interleukin-1β（IL-1β）,Toll-like receptor 4（TLR4）,NLRP3,cleaved caspase-1,caspase-1 were determined by real-time polymerase chain reaction and Western blotting.RESULTS：Pio promoted the survival of retinal cells in GCL following retinal I/R injury（P〈0.05）.Besides,retinal I/R injury stimulated the expression of GFAP and TLR4,which were partially reversed by Pio treatment（P0.05）.Retinal I/R injury-upregulated expression of NLRP3,cleaved caspase-1,IL-1β was attenuated after Pio treatment（P〈0.05）.Moreover,I/R injury induced activation of NF-κB and p38 were inhibited by Pio treatment（P〈0.05）.CONCLUSION：Pio promotes retinal ganglion cells survival by suppressing I/R-induced activation of TLR4/NLRP3 inflammasomes via inhibiting NF-κB and p38 phosphorylation.
